Biocytogen Announces RenLite® Licensing Agreement with Janssen
8.3.2023 16:25:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
Contact information
Biocytogen’s Contacts
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vultr, SUSE & Supermicro Debut Unified Cloud-to-Edge Architecture for Global AI Scaling6.5.2026 15:00:00 EEST | Press release
Vultr, the world's largest privately-held cloud infrastructure company, in collaboration with SUSE and Supermicro, today announces a strategic architectural framework designed to solve the complexities of deploying and operating AI workloads across distributed environments. As AI moves closer to the point of data creation - from manufacturing floors to retail storefronts - organizations face significant challenges in latency, cost and operational consistency. This joint initiative provides a seamless, Cloud-to-Edge pipeline that integrates high-performance hardware, localized cloud infrastructure, and unified Kubernetes management. The partnership addresses the reality that sending all data back to a central cloud is no longer viable for real-time AI. The solution breaks down the infrastructure into three critical layers: The Cloud and Near-Edge - Enterprises can deploy regional Kubernetes-based AI clusters closer to their users by leveraging Vultr’s 33 global cloud data center regions
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program6.5.2026 15:00:00 EEST | Press release
Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solutions across the full drug development lifecycle. Under the collaboration, Waiv will apply its end-to-end computational pathology platform to early phase data. This includes tumor microenvironment (TME) analysis across both hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stained samples, as well as biomarker discovery and outcome prediction capabilities aimed at identifying biomarkers of treatment response ahead of next clinical trial phases. Purpose-built AI approach tackles one of pharma's hardest challenges: b
Elisa Expands PON Deployment with Vecima’s All-PON™ Shelf, Delivering 10G Fiber Services in Estonia6.5.2026 14:30:00 EEST | Press release
Vecima Networks Inc. (TSX: VCM) announced today that leading telecommunications operator Elisa has deployed Vecima’s Entra EXS1610 All-PON™ Shelf for 10G Fiber-to-the-Home (FTTH) services for its subscribers in Estonia. In Estonia’s competitive broadband market, Elisa brings highly innovative solutions to its subscribers. Vecima’s EXS1610 supports multiple deployment use cases, including greenfield, targeted brownfields, rural edge-outs, hybrid fiber-coax (HFC) overbuilds, footprint extensions, and hub collapses. Its compact shelf footprint can help reduce operating costs and allow operators to deploy anywhere – for maximum flexibility, including data centers, remote cabinets, the headend, and multi-dwelling units. The Entra EXS1610 All-PON Shelf features: 16 x PON ports: 10G-EPON, XGS-PON, and Combo XGS-PON & GPON Temperature-hardened for outside plant deployments Multi-vendor optical network terminal (ONT) interoperability Uplink optics: 2 x 100/40G & 2 x 25/10G with broad third-part
Vertex Announces CASGEVY ® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany6.5.2026 14:01:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia. “For the first time in Germany, a long-term, sustainable access agreement to a gene therapy has been established for people living with sickle cell disease and transfusion-dependent beta thalassemia,” said Ludovic Fenaux, Senior Vice President, Vertex International. “This agreement represents significant progress for people living with these two devastating and life-shortening diseases. We are pleased to collaborate across the health care system to ensure the value of CASGEVY is recognized and sustainable patient access is secured.” With this agreement, German
NIQ Launches AI-Powered Platform to Help Brands Test Pricing Decisions Before They Go to Market6.5.2026 14:00:00 EEST | Press release
As manufacturers face mounting pressure to protect margins, justify trade spend, and respond faster to shifting consumer demand, NIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the commercial launch of Price & Promo Optimizer, a next‑generation, AI‑enabled Revenue Growth Management (RGM) platform built to fundamentally change how pricing and promotion decisions are made. Today, many pricing and promotion decisions are still made across disconnected tools, manual workflows, and siloed teams—slowing execution, increasing risk, and limiting the ability to validate strategies before they reach the market. Price & Promo Optimizer replaces this fragmented approach with a united platform that brings pricing, promotion, and trade strategy into a single workflow. Powered by NIQ’s trusted store‑level measurement data and advanced analytical models, Price & Promo Optimizer enables category managers, RGM leaders, marketing, and commercial teams to simulate scenarios, qua
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom